What it means
Glucagon-like peptide-1 is secreted by L-cells in the small intestine when food arrives. It stimulates insulin release in proportion to glucose, suppresses glucagon, slows stomach emptying and acts on the hypothalamus to reduce appetite. Natural GLP-1 lasts about two minutes in blood; the drugs (liraglutide, semaglutide, and the combined GIP/GLP-1 agonist tirzepatide) are modified to last days.
The term "GLP-1" in everyday use now means the drug class — the once-weekly injectables for diabetes and obesity, with triple agonists following.
Why it matters for longevity
Obesity and insulin resistance shorten healthspan more than almost anything else modifiable, and GLP-1 drugs produce 15–22% weight loss where diet alone averages 5–10%. The outcome trials now show lower cardiovascular events, which moves the class from a weight-loss tool to a candidate healthspan intervention — with a muscle-loss caveat that a longevity plan has to manage.
What the evidence says
STEP 1 (Wilding 2021): semaglutide 2.4 mg weekly produced 14.9% weight loss over 68 weeks versus 2.4% on placebo. SURMOUNT-1 (Jastreboff 2022): tirzepatide up to 20.9%. SELECT (Lincoff 2023, 17,600 adults with obesity and heart disease): semaglutide cut major cardiovascular events by 20% over three years, the first hard-outcome result for an obesity drug.
The caveat: 25–40% of the weight lost in these trials was lean mass, as on any rapid weight loss, and weight regain after stopping is the norm (two-thirds regained within a year in STEP 1 extension). Side effects are mainly gastrointestinal; rare signals include pancreatitis and gallbladder disease.
How to measure or use it
- Prescription-only medicines, prescribed and monitored by a physician. The protocol question is how to protect muscle around them: 1.6–2.2 g/kg of protein, resistance training three times a week, a DEXA at baseline and every three months.
- Track HOMA-IR, HbA1c, ApoB and lean mass, not just the scale.
- The exit plan matters as much as the entry: taper, not stop, with the muscle and habits in place first.
Related
- GLP-1 transition guide — how a switch is phased, never stacked
- Tirzepatide (research page) — the dual agonist, studied
- The fat-loss protocol — where the class fits in a plan
Frequently asked questions
How much weight do GLP-1 drugs cause people to lose?
About 15% with semaglutide and 20% with tirzepatide over 16 months in trials, versus 2–3% on placebo.
Do they cause muscle loss?
Roughly a quarter to 40% of weight lost is lean mass, similar to any fast weight loss. Protein and resistance training reduce it.
What happens when you stop?
Most people regain most of the weight within a year unless the habits and muscle are in place. Tapering with a plan is the usual approach.
Want this applied to your own numbers?
Fifteen minutes of intake, your labs, a human-reviewed protocol within about 24 hours, three documents, a free coach call and check-ins through the cycle. €399, follow-up included.
Build my protocol Book a 15-minute call